USA - engelsk - NLM (National Library of Medicine)

physicians total care, inc. - estradiol acetate (unii: 5r97f5h93p) (estradiol - unii:4ti98z838e) - estradiol acetate 0.1 mg in 24 [usp'u] - femring therapy is indicated in the: 1. treatment of moderate to severe vasomotor symptoms due to menopause. 2. treatment of moderate to severe vulvar and vaginal atrophy due to menopause. femring should not be used in women with any of the following conditions: - undiagnosed abnormal genital bleeding. - known, suspected, or history of breast cancer. - known or suspected estrogen-dependent neoplasia. - active deep vein thrombosis, pulmonary embolism or history of these conditions. - active arterial thromboembolic disease (for example, stroke and myocardial infarction) or a history of these conditions. - known liver dysfunction or disease. - known or suspected pregnancy.

USA - engelsk - NLM (National Library of Medicine)

allergan, inc. - estradiol acetate (unii: 5r97f5h93p) (estradiol - unii:4ti98z838e) - estradiol 0.05 mg in 1 d - femring is contraindicated in women with any of the following conditions: - undiagnosed abnormal genital bleeding - known, suspected, or history of breast cancer - known or suspected estrogen-dependent neoplasia - active dvt, pe, or history of these conditions - active arterial thromboembolic disease (for example, stroke and mi), or a history of these conditions - known anaphylactic reaction or angioedema to femring - known liver impairment or disease  - known protein c, protein s, or antithrombin deficiency, or other known thrombophilic disorders - known or suspected pregnancy  femring should not be used during pregnancy [ see   contraindications (4) ] . there appears to be little or no increased risk of birth defects in children born to women who have used estrogens and progestins as an oral contraceptive inadvertently during early pregnancy. femring should not be used during lactation. estrogen administration to nursing women has been shown to decrease the quantity and quality of the breast milk. detectabl

USA - engelsk - NLM (National Library of Medicine)

sandoz inc - estradiol valerate (unii: okg364o896) (estradiol - unii:4ti98z838e) - estradiol valerate 3 mg - estradiol valerate and estradiol valerate/dienogest is indicated for use by women to prevent pregnancy. the efficacy of estradiol valerate and estradiol valerate/dienogest in women with a body mass index (bmi) of > 30 kg/m2 has not been evaluated. estradiol valerate and estradiol valerate/dienogest is also indicated for the treatment of heavy menstrual bleeding in women without organic pathology who choose to use an oral contraceptive as their method of contraception [see clinical studies (14.2)]. do not prescribe estradiol valerate and estradiol valerate/dienogest to women who are known to have the following: there is little or no increased risk of birth defects in women who inadvertently use cocs during early pregnancy. epidemiologic studies and meta-analyses have not found an increased risk of genital or non-genital birth defects (including cardiac anomalies and limb-reduction defects) following exposure to low dose cocs prior to conception or during early pregnancy. the administration of cocs to induce w

USA - engelsk - NLM (National Library of Medicine)

allergan, inc. - estradiol acetate (unii: 5r97f5h93p) (estradiol - unii:4ti98z838e) - estradiol 0.05 mg in 1 d

USA - engelsk - NLM (National Library of Medicine)

millicent us, inc. - estradiol acetate (unii: 5r97f5h93p) (estradiol - unii:4ti98z838e) - femring is contraindicated in women with any of the following conditions: - undiagnosed abnormal genital bleeding - known, suspected, or history of breast cancer - known or suspected estrogen-dependent neoplasia - active dvt, pe, or history of these conditions - active arterial thromboembolic disease (for example, stroke and mi), or a history of these conditions - known anaphylactic reaction or angioedema to femring - known liver impairment or disease - known protein c, protein s, or antithrombin deficiency, or other known thrombophilic disorders - known or suspected pregnancy femring should not be used during pregnancy [ see contraindications (4) ] . there appears to be little or no increased risk of birth defects in children born to women who have used estrogens and progestins as an oral contraceptive inadvertently during early pregnancy. femring should not be used during lactation. estrogen administration to nursing women has been shown to decrease the quantity and quality of the breast

USA - engelsk - NLM (National Library of Medicine)

perrigo company - estradiol valerate (unii: okg364o896) (estradiol - unii:4ti98z838e) - estradiol valerate 20 mg in 1 ml - estradiol valerate injection is indicated in the: 1.    treatment of moderate to severe vasomotor symptoms associated with the menopause. 2.    treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with the menopause.  when prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered. 3.    treatment of hypoestrogenism due to hypogonadism, castration or primary ovarian failure. 4.    treatment of advanced androgen-dependent carcinoma of the prostate (for palliation only). estradiol valerate injection should not be used in women with any of the following conditions: 1.    undiagnosed abnormal genital bleeding. 2.    known, suspected, or history of cancer of the breast. 3.    known or suspected estrogen-dependent neoplasia. 4.    active deep vein thrombosis, pulmonary embolism or a history of these conditions. 5.    active or recent (e.g., within the past year) arterial thromboembolic disease (e.g., stroke, myocardial i

USA - engelsk - NLM (National Library of Medicine)

bayer healthcare pharmaceuticals inc. - estradiol valerate (unii: okg364o896) (estradiol - unii:4ti98z838e) - estradiol valerate 3 mg - natazia® is indicated for use by women to prevent pregnancy. the efficacy of natazia in women with a body mass index (bmi) of > 30 kg/m2 has not been evaluated. natazia is also indicated for the treatment of heavy menstrual bleeding in women without organic pathology who choose to use an oral contraceptive as their method of contraception [see clinical studies (14.2)]. natazia is contraindicated in females who are known to have or develop the following conditions: there is little or no increased risk of birth defects in women who inadvertently use cocs during early pregnancy. epidemiologic studies and meta-analyses have not found an increased risk of genital or non-genital birth defects (including cardiac anomalies and limb-reduction defects) following exposure to low dose cocs prior to conception or during early pregnancy. the administration of cocs to induce withdrawal bleeding should not be used as a test for pregnancy. cocs should not be used during pregnancy to treat threatened or habitual abortion. wo

USA - engelsk - NLM (National Library of Medicine)

pharmacia & upjohn company llc - estradiol cypionate (unii: 7e1dv054lo) (estradiol - unii:4ti98z838e) - estradiol cypionate 5 mg in 1 ml - depo-estradiol injection is indicated in the treatment of: estrogens should not be used in individuals with any of the following conditions: there appears to be little or no increased risk of birth defects in children born to women who have used estrogens and progestins from oral contraceptives inadvertently during early pregnancy. (see precautions.) chlorobutanol anhydrous (chloral derivative) added as a preservative may be habit forming.

USA - engelsk - NLM (National Library of Medicine)

amneal pharmaceuticals of new york llc - estradiol (unii: 4ti98z838e) (estradiol - unii:4ti98z838e) - estradiol 10 ug - estradiol is contraindicated in women with any of the following conditions: - undiagnosed abnormal genital bleeding [see warnings and precautions (5.3)] . - breast cancer or history of breast cancer [see warnings and precautions (5.3)] . - estrogen-dependent neoplasia [see warnings and precautions (5.3)] . - active dvt, pe, or history of these conditions [see warnings and precautions (5.2)] . - active arterial thromboembolic disease (for example, stroke or mi), or a history of these conditions [see warnings and precautions (5.2)] . - known anaphylactic reaction, or angioedema, or hypersensitivity to estradiol [see warnings and precautions (5.16)] . - hepatic impairment or disease. - protein c, protein s, or antithrombin deficiency, or other known thrombophilic disorders. risk summary estradiol is not indicated for use in pregnancy. there are no data with the use of estradiol in pregnant women; however, epidemiologic studies and meta-analyses have not found an increased risk of genital or nongenital birth defects (including cardiac anomalies and limb-reduction defects) following exposure to combined hormonal contraceptives (estrogens and progestins) before conception or during early pregnancy. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. risk summary estrogens are present in human milk and can reduce milk production in breast-feeding females. this reduction can occur at any time but is less likely to occur once breast-feeding is well-established. the developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for estradiol and any potential adverse effects on the breastfed child from estradiol or from the underlying maternal condition. estradiol is not indicated for use in pediatric patients. clinical studies have not been conducted in the pediatric population. there have not been sufficient numbers of geriatric women involved in clinical studies utilizing estradiol to determine whether those over 65 years of age differ from younger subjects in their response to estradiol. the women’s health initiative studies in the whi estrogen-alone substudy (daily ce [0.625 mg]-alone versus placebo), there was a higher relative risk of stroke in women greater than 65 years of age [see clinical studies (14.2) ] . in the whi estrogen plus progestin substudy (daily ce [0.625 mg] plus mpa [2.5 mg] versus placebo), there was a higher relative risk of nonfatal stroke and invasive breast cancer in women greater than 65 years of age [see clinical studies (14.2) ] . the women’s health initiative memory study in the whims ancillary studies of postmenopausal women 65 to 79 years of age, there was an increased risk of developing probable dementia in women receiving estrogen-alone or estrogen plus progestin when compared to placebo [see warnings and precautions (5.4) and clinical studies (14.3) ] . since both ancillary studies were conducted in women 65 to 79 years of age, it is unknown whether these findings apply to younger postmenopausal women8  [see warnings and precautions (5.4) and clinical studies (14.3) ] . estradiol (ess-tra-dye-ole) vaginal inserts read this instructions for use before you start using estradiol vaginal inserts and  each time you get a refill. there may be new information. this information does not take the place of talking to your healthcare provider about your menopausal symptoms or your treatment. how should i use estradiol vaginal inserts? - estradiol vaginal insert is an insert for use only in the vagina. do not take by mouth. - wash and dry your hands well before handling estradiol vaginal insert. step 1: tear off 1 applicator. step 2: pull apart the plastic wrap and remove the applicator (see figure a). if after opening the package you see that the estradiol vaginal insert has come out of the applicator but has not fallen out of the package, carefully put the insert back into the applicator for insertion. figure a step 3: hold the applicator between your thumb and middle finger. leave your index (pointer) finger free to press the applicator plunger (see figure b). figure b step 4: select the best position for vaginal insertion of estradiol vaginal inserts that is most comfortable for you. for insertion in the lying down position, see figure c. for insertion in the standing position, see figure d figure c figure d step 5: gently insert the end of the applicator into your vagina as far as it will comfortably go or until half of the applicator is inside your vagina, whichever is less. do not use force. if the insert falls out of the applicator before insertion, throw away (dispose of) the insert and applicator. get a new applicator. step 6: while holding the applicator in place, gently press the applicator plunger with your index (pointer) finger until it stops, to release the insert into your vagina. the insert will dissolve. step 7: gently remove the applicator from your vagina and throw away (dispose of) after use. insertion may be done at any time of the day. it is advisable to use the same time daily for all applications of estradiol vaginal inserts. if you have any questions, please ask your healthcare provider or pharmacist. how should i store estradiol vaginal inserts? - store estradiol vaginal inserts at room temperature between 68ºf to 77ºf (20ºc to 25ºc). - do not refrigerate. keep estradiol vaginal inserts and all medicines out of the reach of children. this instructions for use has been approved by the u.s. food and drug administration. manufactured by: amneal pharmaceuticals of new york, llc brookhaven, ny 11719 rev. 01-2024-01

USA - engelsk - NLM (National Library of Medicine)

nucare pharmaceuticals, inc - estradiol (unii: 4ti98z838e) (estradiol - unii:4ti98z838e) - estradiol 1 mg - estradiol tablets are indicated in the: - treatment of moderate to severe vasomotor symptoms associated with the menopause. - treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with the menopause. when prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered. - treatment of hypoestrogenism due to hypogonadism, castration or primary ovarian failure. - treatment of breast cancer (for palliation only) in appropriately selected women and men with metastatic disease. - treatment of advanced androgen-dependent carcinoma of the prostate (for palliation only). - prevention of osteoporosis. when prescribing solely for the prevention of postmenopausal osteoporosis, therapy should only be considered for women at significant risk of osteoporosis and for whom non-estrogen medications are not considered to be appropriate. (see clinical pharmacology , clinical studies. ) - the m